CLU and Familial prostate cancer: CLU was found to be expressed at a lower level in the high-risk C3 subtype of prostate cancer, with significantly less infiltration of CD8 T cells, monocytes, resting dendritic cells, activated dendritic cells, and activated mast cells, implying that CLU may influence immune cell infiltration through some mechanism (Zhang et al., 2020).